These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35755947)

  • 1. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application.
    Kitano Y; Nishimura S; Kato TM; Ueda A; Takigawa K; Umekage M; Nomura M; Kawakami A; Ogawa H; Xu H; Hotta A; Takasu N; Tsukahara M
    Mol Ther Methods Clin Dev; 2022 Sep; 26():15-25. PubMed ID: 35755947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).
    Thongsin N; Wattanapanitch M
    Methods Mol Biol; 2022; 2454():607-624. PubMed ID: 33945142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
    Xu H; Wang B; Ono M; Kagita A; Fujii K; Sasakawa N; Ueda T; Gee P; Nishikawa M; Nomura M; Kitaoka F; Takahashi T; Okita K; Yoshida Y; Kaneko S; Hotta A
    Cell Stem Cell; 2019 Apr; 24(4):566-578.e7. PubMed ID: 30853558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine.
    Trionfini P; Romano E; Varinelli M; Longaretti L; Rizzo P; Giampietro R; Caroli A; Aiello S; Todeschini M; Casiraghi F; Remuzzi G; Benigni A; Tomasoni S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
    Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
    Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
    Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
    Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a homozygous CIITA knockout iPS cell line using the CRISPR-Cas9 system.
    Romano E; Trionfini P; Giampietro R; Benigni A; Tomasoni S
    Stem Cell Res; 2021 Dec; 57():102580. PubMed ID: 34688128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of homozygous Na
    Maurer W; Hartmann N; Argyriou L; Sossalla S; Streckfuss-Bömeke K
    Stem Cell Res; 2022 Apr; 60():102677. PubMed ID: 35092938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-the-Shelf, Immune-Compatible Human Embryonic Stem Cells Generated Via CRISPR-Mediated Genome Editing.
    Kim A; Lee KG; Kwon Y; Lee KI; Yang HM; Habib O; Kim J; Kim ST; Kim SJ; Kim JS; Hwang DY
    Stem Cell Rev Rep; 2021 Jun; 17(3):1053-1067. PubMed ID: 33423156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells.
    Kwon YW; Ahn HS; Lee JW; Yang HM; Cho HJ; Kim SJ; Lee SH; Yang HM; Jang HD; Kim SJ; Kim HS
    Stem Cells Int; 2021; 2021():8873383. PubMed ID: 34093711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and future perspectives of HLA-edited induced pluripotent stem cells.
    Koga K; Wang B; Kaneko S
    Inflamm Regen; 2020; 40():23. PubMed ID: 33014207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-based banking of induced pluripotent stem cells in Saudi Arabia.
    Alowaysi M; Lehmann R; Al-Shehri M; Baadhaim M; Alzahrani H; Aboalola D; Zia A; Malibari D; Daghestani M; Alghamdi K; Haneef A; Jawdat D; Hakami F; Gomez-Cabrero D; Tegner J; Alsayegh K
    Stem Cell Res Ther; 2023 Dec; 14(1):374. PubMed ID: 38111036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress of national banking project on homozygous HLA-typed induced pluripotent stem cells in South Korea.
    Rim YA; Park N; Nam Y; Ham DS; Kim JW; Ha HY; Jung JW; Jung SM; Baek IC; Kim SY; Kim TG; Song J; Lee J; Park SH; Chung NG; Yoon KH; Ju JH
    J Tissue Eng Regen Med; 2018 Mar; 12(3):e1531-e1536. PubMed ID: 28941241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-Mediated Genome Editing to Generate Clonal iPSC Lines.
    Sanjurjo-Soriano C; Erkilic N; Mamaeva D; Kalatzis V
    Methods Mol Biol; 2022; 2454():589-606. PubMed ID: 33755901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of NPHP1 knockout human pluripotent stem cells by a practical biallelic gene deletion strategy using CRISPR/Cas9 and ssODN.
    Nakano Y; Susa K; Yanagi T; Hiraoka Y; Suzuki T; Mori T; Ando F; Mandai S; Fujiki T; Rai T; Uchida S; Sohara E
    In Vitro Cell Dev Biol Anim; 2022 Feb; 58(2):85-95. PubMed ID: 35165826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
    Dannenmann B; Nasri M; Welte K; Skokowa J
    Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
    Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
    Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.